Cybin Inc. (NASDAQ:HELP - Get Free Report) has been assigned a consensus rating of "Buy" from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $58.75.
A number of equities analysts have recently weighed in on the stock. TD Cowen began coverage on shares of Cybin in a research report on Monday, April 13th. They issued a "buy" rating for the company. Jefferies Financial Group assumed coverage on shares of Cybin in a research note on Monday, February 2nd. They issued a "buy" rating and a $22.00 target price for the company. Finally, HC Wainwright boosted their price target on Cybin from $55.00 to $95.00 and gave the company a "buy" rating in a report on Monday, March 2nd.
View Our Latest Stock Analysis on HELP
Hedge Funds Weigh In On Cybin
Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its stake in Cybin by 66.8% in the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company's stock worth $247,000 after buying an additional 11,790 shares during the last quarter. Osaic Holdings Inc. increased its stake in shares of Cybin by 46.7% during the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company's stock valued at $63,000 after acquiring an additional 2,400 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Cybin by 1,388.5% during the 4th quarter. Millennium Management LLC now owns 1,028,549 shares of the company's stock worth $8,414,000 after acquiring an additional 959,448 shares during the period. 17.94% of the stock is currently owned by institutional investors and hedge funds.
Cybin Trading Down 3.6%
Cybin stock opened at $5.34 on Friday. The stock's 50-day moving average is $5.47. Cybin has a 52 week low of $4.29 and a 52 week high of $9.83. The stock has a market cap of $275.70 million, a PE ratio of -1.26 and a beta of 0.80.
Cybin (NASDAQ:HELP - Get Free Report) last released its earnings results on Friday, February 13th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.19). Equities research analysts predict that Cybin will post -4.08 EPS for the current fiscal year.
Cybin Company Profile
(
Get Free Report)
Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.
The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.